<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04851457</url>
  </required_header>
  <id_info>
    <org_study_id>2021-OPTIMISTIC</org_study_id>
    <nct_id>NCT04851457</nct_id>
  </id_info>
  <brief_title>One Pass Tirofiban In Management of Ischemic Stroke Thrombectomy In China</brief_title>
  <acronym>OPTIMISTIC</acronym>
  <official_title>Safety and Efficacy of Tirofiban in Acute Ischemic Stroke Patients Treated With Mechanical Thrombectomy-A Prospective, Randomized, Controlled, Open-Label, Assessor-Blind, Multicenter Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai East Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shanghai 6th People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Qilu Hospital of Shandong University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ningbo No. 1 Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai East Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      In recent years, the positive results of trials for mechanical thrombectomy (MT) have brought&#xD;
      a new era for large artery occlusion patients, especially those beyond the time window of&#xD;
      intravenous thrombolysis. However, interventional procedures can cause endothelial injuries&#xD;
      leading to local activation of platelet aggregation and subsequent thromboembolic&#xD;
      complications or early re-occlusion.Tirofiban is a specific antagonist of the platelet&#xD;
      glycoprotein (GP) IIb/IIIa receptor, which is considered highly effective against the final&#xD;
      common pathway of platelet aggregation and preventing vascular reocclusion. However, there is&#xD;
      no consensus on if AIS patients treated with MT also benefit from intravenous tirofiban. This&#xD;
      study aims to evaluate the effectiveness and safety of profiles of tirofiban during MT and&#xD;
      provide reliable clinical evidence for the treatment of tirofiban in AIS patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a multicenter, prospective, open-label, randomized controlled, blinded-endpoint&#xD;
      trial with two parallel groups and a 3-month follow-up. A total of 200 eligible participants&#xD;
      recruited from 4-6 stroke centers will be randomly allocated to either an experimental group&#xD;
      (intravenous tirofiban + MT therapy) or a control group (MT alone) in a 1:1 ratio. The&#xD;
      primary outcome is a composite endpoint, including the rate of recanalisation after the first&#xD;
      embolectomy and the risk of symptomatic intracerebral haemorrhage. The secondary outcomes&#xD;
      include clinical and neuroimaging outcomes, procedure-related complications, and adverse&#xD;
      events to evaluate the effects of MT in combination with tirofiban treatment compared to MT&#xD;
      alone in AIS patients. Intention-to-treat (ITT) analysis will be undertaken in this study,&#xD;
      and the full analysis set (FAS) population serves as the primary population for the analysis&#xD;
      of efficacy data.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2021</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A prospective, randomized, controlled, open-Label, assessor-blind, multicenter clinical study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Images from each study site will be uploaded to the central server and all analyses will be performed by a trained physician at the study coordinating center who is unaware of group assignments. Similarly, follow-up assessments at 90 days after stroke will be conducted by a trained accessor in a blinded manner.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Composite rates of target vessel revascularization and no symptomatic intracerebral haemorrhage</measure>
    <time_frame>24-72hours after thrombectomy;</time_frame>
    <description>Target vessel revascularization is defined as a modified thrombolysis in cerebral infarction (mTICI) grade after onepass thrombectomy procedure over grade 2b. Symptomatic intracerebral haemorrhage is defined according to per Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST) criteria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recanalisation rates of the target vessel</measure>
    <time_frame>24-72 hours after thrombectomy;</time_frame>
    <description>Neuroimaging outcomes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dichotomized mRS score/ ordinal mRS score</measure>
    <time_frame>The 90-day after randomisation</time_frame>
    <description>Functional prognosis of the patient，clinical outcomes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptomatic intracerebral haemorrhage</measure>
    <time_frame>By the end of the 90-day follow-up</time_frame>
    <description>procedure-related complications and adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death</measure>
    <time_frame>By the end of the 90-day follow-up</time_frame>
    <description>procedure-related complications and adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of thrombectomy times</measure>
    <time_frame>By the end of the 90-day follow-up</time_frame>
    <description>Treatment information</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>Intervention group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The participants in the experimental group will receive intravenous tirofiban combined with a standard MT protocol recommended by the current guidelines for the management of AIS</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients are treated with MT therapy with no antiplatelet drugs (intravenous or intra-arterial) are administered. Besides, they will receive a standard pharmacological treatment as per current clinical guidelines.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravenous tirofiban combination therapy</intervention_name>
    <description>Patients will enter the tirofiban treatment protocol immediately within half an hour after randomization and prior to the femoral artery puncture. Tirofiban is administered as an intravenous bolus dose of 10 μg/kg injection within 3 min and then by an intravenous infusion at a rate of 0.1 μg/(kg·min) for 24 hours.</description>
    <arm_group_label>Intervention group</arm_group_label>
    <other_name>Tirofiban</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female between the ages of 18 and 80;&#xD;
&#xD;
          2. Acute ischemic stroke patients within 4.5-24 hours of stroke onset, with NIHSS scores&#xD;
             &gt; 5;&#xD;
&#xD;
          3. Patients with large vessel occlusion including occlusion of the internal carotid&#xD;
             artery (ICA) termination or middle cerebral artery (MCA, M1, or M2 segment), and who&#xD;
             are scheduled to receive arterial thrombectomy;&#xD;
&#xD;
          4. Complete an assessment with multimodal CT and meet the criteria as follow: penumbra&#xD;
             volume &gt; 10ml, infarct core volume &lt; 70ml, mismatch ratio &gt; 1.2;&#xD;
&#xD;
          5. Patients planning to receive arterial thrombectomy treatment;&#xD;
&#xD;
          6. All patients (or guardians of patients) provided written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with a medical history of atrial fibrillation or atrial flutter, or a 12-lead&#xD;
             electrocardiogram at admission, showing atrial flutter or atrial fibrillation;&#xD;
&#xD;
          2. Patients who have received intravenous thrombolysis;&#xD;
&#xD;
          3. Pre-existing functional impairment with an mRS score ≥ 2;&#xD;
&#xD;
          4. With severe comorbidities (e.g. severe cardiopulmonary insufficiency, advanced&#xD;
             malignancy with an expected survival of less than 90d);&#xD;
&#xD;
          5. More than 1/3 areas of hypodense ischaemic changes supplied by the middle cerebral&#xD;
             artery on baseline CT;&#xD;
&#xD;
          6. Patients with known hypersensitivity or contraindications to the use of tirofiban;&#xD;
&#xD;
          7. Patients with known hypersensitivity or contraindications to the use of contrast&#xD;
             agents in multimodal CT/MRI examinations;&#xD;
&#xD;
          8. Pregnant or lactating women;&#xD;
&#xD;
          9. Patients who are currently participating in other clinical trial;&#xD;
&#xD;
         10. Other conditions judged by the investigator to be inappropriate for inclusion in the&#xD;
             clinical study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gang Li</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai East Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gang Li</last_name>
    <phone>+8618017187086</phone>
    <email>ligang@tongji.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Feifeng Liu</last_name>
    <phone>+8615121100573</phone>
    <email>liufeifeng7@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Gang Li</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200123</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Goyal M, Demchuk AM, Menon BK, Eesa M, Rempel JL, Thornton J, Roy D, Jovin TG, Willinsky RA, Sapkota BL, Dowlatshahi D, Frei DF, Kamal NR, Montanera WJ, Poppe AY, Ryckborst KJ, Silver FL, Shuaib A, Tampieri D, Williams D, Bang OY, Baxter BW, Burns PA, Choe H, Heo JH, Holmstedt CA, Jankowitz B, Kelly M, Linares G, Mandzia JL, Shankar J, Sohn SI, Swartz RH, Barber PA, Coutts SB, Smith EE, Morrish WF, Weill A, Subramaniam S, Mitha AP, Wong JH, Lowerison MW, Sajobi TT, Hill MD; ESCAPE Trial Investigators. Randomized assessment of rapid endovascular treatment of ischemic stroke. N Engl J Med. 2015 Mar 12;372(11):1019-30. doi: 10.1056/NEJMoa1414905. Epub 2015 Feb 11.</citation>
    <PMID>25671798</PMID>
  </reference>
  <reference>
    <citation>Jovin TG, Chamorro A, Cobo E, de Miquel MA, Molina CA, Rovira A, San Román L, Serena J, Abilleira S, Ribó M, Millán M, Urra X, Cardona P, López-Cancio E, Tomasello A, Castaño C, Blasco J, Aja L, Dorado L, Quesada H, Rubiera M, Hernandez-Pérez M, Goyal M, Demchuk AM, von Kummer R, Gallofré M, Dávalos A; REVASCAT Trial Investigators. Thrombectomy within 8 hours after symptom onset in ischemic stroke. N Engl J Med. 2015 Jun 11;372(24):2296-306. doi: 10.1056/NEJMoa1503780. Epub 2015 Apr 17.</citation>
    <PMID>25882510</PMID>
  </reference>
  <reference>
    <citation>Nogueira RG, Jadhav AP, Haussen DC, Bonafe A, Budzik RF, Bhuva P, Yavagal DR, Ribo M, Cognard C, Hanel RA, Sila CA, Hassan AE, Millan M, Levy EI, Mitchell P, Chen M, English JD, Shah QA, Silver FL, Pereira VM, Mehta BP, Baxter BW, Abraham MG, Cardona P, Veznedaroglu E, Hellinger FR, Feng L, Kirmani JF, Lopes DK, Jankowitz BT, Frankel MR, Costalat V, Vora NA, Yoo AJ, Malik AM, Furlan AJ, Rubiera M, Aghaebrahim A, Olivot JM, Tekle WG, Shields R, Graves T, Lewis RJ, Smith WS, Liebeskind DS, Saver JL, Jovin TG; DAWN Trial Investigators. Thrombectomy 6 to 24 Hours after Stroke with a Mismatch between Deficit and Infarct. N Engl J Med. 2018 Jan 4;378(1):11-21. doi: 10.1056/NEJMoa1706442. Epub 2017 Nov 11.</citation>
    <PMID>29129157</PMID>
  </reference>
  <reference>
    <citation>Albers GW, Marks MP, Kemp S, Christensen S, Tsai JP, Ortega-Gutierrez S, McTaggart RA, Torbey MT, Kim-Tenser M, Leslie-Mazwi T, Sarraj A, Kasner SE, Ansari SA, Yeatts SD, Hamilton S, Mlynash M, Heit JJ, Zaharchuk G, Kim S, Carrozzella J, Palesch YY, Demchuk AM, Bammer R, Lavori PW, Broderick JP, Lansberg MG; DEFUSE 3 Investigators. Thrombectomy for Stroke at 6 to 16 Hours with Selection by Perfusion Imaging. N Engl J Med. 2018 Feb 22;378(8):708-718. doi: 10.1056/NEJMoa1713973. Epub 2018 Jan 24.</citation>
    <PMID>29364767</PMID>
  </reference>
  <reference>
    <citation>Kellert L, Hametner C, Rohde S, Bendszus M, Hacke W, Ringleb P, Stampfl S. Endovascular stroke therapy: tirofiban is associated with risk of fatal intracerebral hemorrhage and poor outcome. Stroke. 2013 May;44(5):1453-5. doi: 10.1161/STROKEAHA.111.000502. Epub 2013 Mar 5.</citation>
    <PMID>23463755</PMID>
  </reference>
  <reference>
    <citation>Teng D, Pannell JS, Rennert RC, Li J, Li YS, Wong VW, Chien S, Khalessi AA. Endothelial trauma from mechanical thrombectomy in acute stroke: in vitro live-cell platform with animal validation. Stroke. 2015 Apr;46(4):1099-106. doi: 10.1161/STROKEAHA.114.007494. Epub 2015 Feb 24.</citation>
    <PMID>25712942</PMID>
  </reference>
  <reference>
    <citation>Muñiz-Lozano A, Rollini F, Franchi F, Angiolillo DJ. Update on platelet glycoprotein IIb/IIIa inhibitors: recommendations for clinical practice. Ther Adv Cardiovasc Dis. 2013 Aug;7(4):197-213. doi: 10.1177/1753944713487781. Epub 2013 Jul 1. Review.</citation>
    <PMID>23818658</PMID>
  </reference>
  <reference>
    <citation>Yang J, Wu Y, Gao X, Bivard A, Levi CR, Parsons MW, Lin L; INSPIRE Study Group†. Intraarterial Versus Intravenous Tirofiban as an Adjunct to Endovascular Thrombectomy for Acute Ischemic Stroke. Stroke. 2020 Oct;51(10):2925-2933. doi: 10.1161/STROKEAHA.120.029994. Epub 2020 Sep 16.</citation>
    <PMID>32933416</PMID>
  </reference>
  <reference>
    <citation>Yang M, Huo X, Gao F, Wang A, Ma N, Shi H, Chen W, Wang S, Wang Y, Miao Z. Low-dose rescue tirofiban in mechanical thrombectomy for acute cerebral large-artery occlusion. Eur J Neurol. 2020 Jun;27(6):1056-1061. doi: 10.1111/ene.14170. Epub 2020 Mar 17.</citation>
    <PMID>32048389</PMID>
  </reference>
  <reference>
    <citation>Neuberger U, Seker F, Schönenberger S, Nagel S, Ringleb PA, Bendszus M, Pfaff JAR, Möhlenbruch MA. Prediction of intracranial hemorrhages after mechanical thrombectomy of basilar artery occlusion. J Neurointerv Surg. 2019 Dec;11(12):1181-1186. doi: 10.1136/neurintsurg-2019-014939. Epub 2019 Jun 1.</citation>
    <PMID>31154353</PMID>
  </reference>
  <reference>
    <citation>Wu Y, Yin C, Yang J, Jiang L, Parsons MW, Lin L. Endovascular Thrombectomy. Stroke. 2018 Nov;49(11):2783-2785. doi: 10.1161/STROKEAHA.118.022919.</citation>
    <PMID>30355186</PMID>
  </reference>
  <reference>
    <citation>Guo Y, Lin Y, Tang Y, Tang Q, Wang X, Pan X, Zou J, Yang J. Safety and efficacy of early antiplatelet therapy in acute ischemic stroke patients receiving endovascular treatment: A systematic review and meta-analysis. J Clin Neurosci. 2019 Aug;66:45-50. doi: 10.1016/j.jocn.2019.05.028. Epub 2019 May 29.</citation>
    <PMID>31153752</PMID>
  </reference>
  <reference>
    <citation>Zhou J, Gao Y, Ma QL. Safety and efficacy of tirofiban in acute ischemic stroke patients not receiving endovascular treatment: a systematic review and meta-analysis. Eur Rev Med Pharmacol Sci. 2020 Feb;24(3):1492-1503. doi: 10.26355/eurrev_202002_20208.</citation>
    <PMID>32096199</PMID>
  </reference>
  <reference>
    <citation>Sun Y, Guo ZN, Yan X, Wang M, Zhang P, Qin H, Wang Y, Zhu H, Yang Y. Safety and efficacy of tirofiban combined with endovascular therapy compared with endovascular therapy alone in acute ischemic stroke: a meta-analysis. Neuroradiology. 2021 Jan;63(1):17-25. doi: 10.1007/s00234-020-02530-9. Epub 2020 Aug 25.</citation>
    <PMID>32844236</PMID>
  </reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 11, 2021</study_first_submitted>
  <study_first_submitted_qc>April 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 20, 2021</study_first_posted>
  <last_update_submitted>April 15, 2021</last_update_submitted>
  <last_update_submitted_qc>April 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute Ischemic Stroke</keyword>
  <keyword>Tirofiban</keyword>
  <keyword>Mechanical thrombectomy</keyword>
  <keyword>Revascularisation</keyword>
  <keyword>Haemorrhage</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemic Stroke</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tirofiban</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

